The Inflation Reduction Act’s Implications For Employer-Sponsored Health Plans

The Inflation Reduction Act (IRA) aims to lower prescription drug costs and enhance Medicare benefits. While these changes benefit Medicare recipients, they raise concerns for employer-sponsored health plans that are not part of government price negotiations. These plans could see cost increases due to price shifts, with premiums rising for employers and employees alike. The primary concern is that non-Medicare participants will bear these higher costs as pharmaceutical companies and health care providers raise prices to offset lost revenue.

Historically, Medicare’s cost reductions have led to higher prices for employer-sponsored plans. When Medicare sets lower prices for services under Parts A (hospital) and B (outpatient), providers often shift costs to those with private insurance to maintain profitability. This trend is expected to continue under the IRA. As Medicare negotiates lower prescription drug prices, hospitals, physicians and drug manufacturers may compensate for lost revenue by charging higher prices to private insurers and employer-sponsored health plans, following patterns seen over the last four decades.

Plan sponsors and benefits advisors must proactively prepare for these changes by implementing cost management strategies, negotiating better pricing and educating employees on health care options. Ultimately, while the IRA provides relief to Medicare recipients, it places a financial burden on those outside of government-negotiated pricing structures.

By being prepared and implementing strategic solutions, employers can mitigate some of the financial pressures that may arise from the IRA, ensuring that their employees and retirees are better protected from the ripple effects of this landmark legislation.

Medicare Part D redesign and reinsurance adjustments under the IRA

The IRA introduces major changes to Medicare Part D in 2025, including a $2,000 annual out-of-pocket cap for prescription drugs, which will significantly reduce costs for Medicare beneficiaries.

In addition to redesigning Part D, the IRA reduces Medicare’s reinsurance payments from covering 80% of catastrophic drug costs to just 20% for brand-name drugs and 40% for generics. This shift further burdens private health plans, which will need to absorb more of the rising drug costs. While Medicare premiums are capped at a 6% growth rate, the underlying costs of prescription drug coverage for employer-sponsored plans are expected to continue rising.

Impact on employer-sponsored health plans: Rising costs for retiree and employee plans

Employer-sponsored plans, whether for retirees or active employees, will likely face significant cost increases due to the IRA. Private health plans, unlike Medicare, do not benefit from government-negotiated drug prices. As Medicare’s drug costs decrease, private plans may experience higher drug prices, particularly for expensive specialty drugs. This dynamic creates financial pressure for employers, who must decide whether to absorb these cost increases or pass them on to retirees and employees through higher premiums and/or point of purchase cost sharing.

Retiree health plans Retirees enrolled in employer-sponsored health plans are especially vulnerable. As Medicare prescription drug prices decrease, retirees on fixed incomes may face higher premiums as private plans adjust to cover the rising costs of drugs not covered by Medicare. Retirees, many of whom are on fully insured plans, could end up bearing the full cost of these increases, leading to financial strain and difficult decisions about health care coverage.

Employee health plans Similarly, active employees could face higher premiums and out-of-pocket expenses as pharmaceutical companies and health care providers adjust prices to offset revenue losses from Medicare price negotiations. Employers, in turn, may respond to these rising costs by reducing plan benefits, increasing deductibles, or passing on higher premiums to employees. Specialty drugs, which are often critical to managing chronic conditions, could be particularly affected, causing further financial strain on employees and their families.

Long-term outlook: Drug price negotiations and further cost shifting

Beginning in 2026, the IRA mandates that Medicare negotiate prices for the top 10 most-prescribed drugs. This change is projected to save Medicare approximately $26 billion, significantly lowering prescription costs for beneficiaries. However, these savings may come at a cost to employer-sponsored plans. As drug manufacturers lose revenue from Medicare negotiations, they are likely to shift these costs to private health plans, increasing prices for employers and employees.

The disparity between Medicare’s negotiating power and private plans’ lack of leverage will likely lead to significant price increases for employer-sponsored health plans. According to a recent study, on average, private insurance plans pay 250+% more than Medicare for the same health care services from the same provider! As more drugs come under Medicare’s price negotiation, cost-shifting to private plans will likely intensify, leaving employers and their employees to bear the burden of rising health care costs.

The Inflation Reduction Act represents a significant shift in U.S. health care policy, particularly in how prescription drug prices are regulated. While it offers considerable savings for Medicare beneficiaries, it also poses challenges for employer-sponsored health plans. Cost shifting from Medicare to private plans, rising premiums for retirees and higher out-of-pocket costs for employees are all likely outcomes.

 

Source Link

Recommended Articles

CMS Distributes $10B To Strengthen Rural Health Care Access

The Centers for Medicare & Medicaid Services will distribute $10 billion among all 50 states during the second year of the Rural Health Transformation Program. This funding is intended to build on early progress and deliver lasting improvements in access, quality and health outcomes for rural Americans. “President Trump made a historic investment in rural ...

Read More

What Your Health Benefits Advisor Wishes You Knew Before Choosing A Plan

A family can pay their health insurance premium every month and still hesitate to see a doctor because of what the visit might cost. Or worse, an employee may believe the plan they chose through their company covers a specialist, only to learn it does not once they are at the provider’s office. Misunderstandings can ...

Read More

Feds Invite Industry To Test Electronic Prior Auth Readiness

The federal government is inviting health insurance companies, hospitals and electronic health record companies to test their readiness for upcoming electronic prior authorization requirements. The Office of the National Coordinator for Health Information Technology, the Health and Human Services Department and the Centers for Medicare and Medicaid Services announced Thursday they will hold voluntary 10-12 ...

Read More

Google Cloud Rolls Out Gemini For Healthcare

Google launched Tuesday Gemini for healthcare, an agentic artificial intelligence platform aimed at connecting complex clinical, financial and administrative workflows used by healthcare providers and payers. The platform was developed alongside clinical and health plan leaders and is built to support HIPAA compliance, the tech giant said. “The fundamental challenge in healthcare isn’t a lack ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square